Fenbendazole

A 2025 study showed fenbendazole targets cancer stem cells — which survive chemotherapy and regrow tumors — achieving 100% survival in treated mice versus zero in untreated controls. Fenbendazole brought three stage-4 cancer patients into complete remission in 2025. Fenbendazole is an inexpensive antiparasitic drug costing $5–$12 with an expired patent, originally developed to kill parasitic worms. No major cancer center is conducting clinical trials on fenbendazole because its expired patent makes pharmaceutical investment financially unrecoverable. Most fenbendazole cancer research originates from universities in South Korea and India with no industry funding and no conflicts of interest. Fenbendazole works by binding directly to tubulin proteins, breaking down the cytoskeletal scaffold cancer cells require for division.